XOMA Corporation (XOMA)
After hours:
| Previous Close | 25.08 |
| Open | 25.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 24.43 - 25.48 |
| 52 Week Range | 13.48 - 27.00 |
| Volume | |
| Avg. Volume | 15,014 |
| Market Cap | 289.918M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.92 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | 2.16 (8.66%) |
| Ex-Dividend Date | Apr 02, 2024 |
| 1y Target Est | 58.00 |
GlobeNewswireXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET. The presentation can be accessed at https://bit.l
GuruFocus.comXOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss
Comprehensive Analysis of XOMA's Financial Performance and Strategic Highlights
- GlobeNewswire
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well
